B. Riley Lowers Earnings Estimates for Rigel Pharmaceuticals

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) – Equities research analysts at B. Riley lowered their Q2 2025 earnings per share (EPS) estimates for shares of Rigel Pharmaceuticals in a research note issued to investors on Tuesday, May 6th. B. Riley analyst K. Patel now anticipates that the biotechnology company will post earnings per share of $0.14 for the quarter, down from their prior forecast of $0.18. B. Riley has a “Neutral” rating and a $24.00 price objective on the stock. The consensus estimate for Rigel Pharmaceuticals’ current full-year earnings is $0.22 per share. B. Riley also issued estimates for Rigel Pharmaceuticals’ Q3 2025 earnings at $0.08 EPS, Q4 2025 earnings at $0.16 EPS and FY2027 earnings at $1.44 EPS.

Rigel Pharmaceuticals (NASDAQ:RIGL) last issued its quarterly earnings results on Tuesday, May 6th. The biotechnology company reported $0.63 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.14 by $0.49. Rigel Pharmaceuticals had a net margin of 2.46% and a negative return on equity of 14.80%. The company had revenue of $53.33 million during the quarter, compared to the consensus estimate of $43.87 million. During the same quarter in the previous year, the firm earned ($0.50) earnings per share.

Other research analysts also recently issued research reports about the company. StockNews.com downgraded Rigel Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, March 8th. Cantor Fitzgerald lifted their target price on Rigel Pharmaceuticals from $20.00 to $23.00 and gave the stock a “neutral” rating in a research report on Wednesday. HC Wainwright reaffirmed a “buy” rating and set a $57.00 price target on shares of Rigel Pharmaceuticals in a research report on Wednesday, March 5th. Finally, Citigroup raised their target price on shares of Rigel Pharmaceuticals from $49.00 to $55.00 and gave the stock a “buy” rating in a research report on Thursday, March 6th. Three research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $36.40.

Rigel Pharmaceuticals Price Performance

NASDAQ:RIGL opened at $18.96 on Friday. The firm has a market capitalization of $338.81 million, a PE ratio of 135.46 and a beta of 1.34. The business’s fifty day moving average price is $18.63 and its 200 day moving average price is $19.76. Rigel Pharmaceuticals has a 12 month low of $7.48 and a 12 month high of $29.82.

Hedge Funds Weigh In On Rigel Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. China Universal Asset Management Co. Ltd. acquired a new stake in Rigel Pharmaceuticals in the fourth quarter valued at about $63,000. US Bancorp DE boosted its stake in shares of Rigel Pharmaceuticals by 57.4% in the first quarter. US Bancorp DE now owns 5,120 shares of the biotechnology company’s stock valued at $92,000 after buying an additional 1,868 shares in the last quarter. New York State Common Retirement Fund raised its position in Rigel Pharmaceuticals by 65.9% in the first quarter. New York State Common Retirement Fund now owns 5,536 shares of the biotechnology company’s stock worth $100,000 after acquiring an additional 2,200 shares in the last quarter. Wells Fargo & Company MN boosted its position in shares of Rigel Pharmaceuticals by 44.5% during the 4th quarter. Wells Fargo & Company MN now owns 8,603 shares of the biotechnology company’s stock worth $145,000 after purchasing an additional 2,648 shares in the last quarter. Finally, SG Americas Securities LLC increased its holdings in shares of Rigel Pharmaceuticals by 42.8% in the 4th quarter. SG Americas Securities LLC now owns 9,429 shares of the biotechnology company’s stock valued at $159,000 after purchasing an additional 2,827 shares in the last quarter. 66.23% of the stock is currently owned by hedge funds and other institutional investors.

Rigel Pharmaceuticals Company Profile

Rigel Pharmaceuticals, Inc, a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company’s commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer.